miDiagnostics

Executive Summary

miDiagnostics, a Belgian diagnostics company founded in 2015, is pioneering ultra-fast, high-precision molecular diagnostic tests using a proprietary silicon chip-based nanofluidic processor. This innovative platform enables sample-to-answer results in under 30 minutes, addressing the critical need for rapid and reliable point-of-care testing. By leveraging semiconductor manufacturing techniques, the company aims to reduce costs and improve accessibility, positioning itself as a disruptive force in the global diagnostics market. With a focus on infectious disease and other acute conditions, miDiagnostics seeks to democratize advanced molecular diagnostics, moving testing from centralized labs to decentralized settings such as clinics, pharmacies, and home use. The company's technology has the potential to significantly impact patient outcomes by enabling earlier diagnosis and treatment decisions. While currently private and in a growth stage, miDiagnostics has attracted attention for its novel approach to nanofluidics. The key challenges include regulatory approvals, scaling manufacturing, and competing with established point-of-care players. However, the strong intellectual property portfolio and the shift toward decentralized testing present substantial opportunities. If successful, miDiagnostics could become a key player in the rapidly evolving diagnostics landscape, addressing both developed and emerging market needs.

Upcoming Catalysts (preview)

• Q4 2026CE Marking for flagship diagnostic test65% success
• Q2 2027Series B/C funding round to commercialize platform70% success
• Q3 2026Strategic partnership with global diagnostics distributor60% success